💡 Meanwhile, in major pharmaceutical news...What's the future of healthcare? 👩🔬 After launching several new, effective medicines and vaccines this year, Paul Hudson and his team at Sanofi have also received regulatory approval for a new treatment in lung disease. 🤖 Amongst these developments, they have also launched Modulus, a new type of AI powered factory that produces multiple vaccines and medicines at a faster rate which will only help the response time for future health crises. As Sanofi looks to focus on developing new medicines and treatments, they look to capitalize on becoming a pure-play biopharma organization by spinning off its consumer health business. 🔬 What does this mean for the industry...? - Innovation: They are leading the way in medicine manufacturing with AI, bringing a positive sign for the industry. - Patient Access: They are improving the health and well-being of millions as they strive for groundbreaking new treatments. - Industry Consolidation: Sanofi's decision to focus solely on biopharma could lead further organizations to specialize and focus on their core competencies. ⁉ What other impacts can you see Sanofi having on the industry? Is Big Biotech on the way? What are you most excited about in the future of healthcare? 🗯 Share your thoughts below! #HealthcareFuture, #Innovation, #PatientCentered
We finished Q3 strong, with broad-based, double-digit sales growth propelled by our launches of best-in-class medicines and vaccines. The momentum of our Sanofi pipeline continues this quarter, with a sustained cadence of positive phase 3 data and major regulatory approvals, including three in a row - EU, US & China - for the first-ever biologic for certain adults with uncontrolled Chronic Obstructive Pulmonary Disease. Our modernization is taking shape every day at an incredible pace. Last month, we inaugurated Modulus, the first AI-powered factory of the future. Modulus can manufacture up to four vaccines or biomedicines at a time, with the unique ability to quickly adapt in a matter of days in response to health challenges around the world. It’s one factory, but with infinite possibilities. We’re also progressing with our strategy to create a focused player in Consumer Healthcare, giving Opella the opportunity to thrive as a global leader and paving the way for Sanofi to become a pure-play, science-driven biopharma company. Looking to the future, I’m confident in the course we’ve charted and excited about what’s to come. Not only for Sanofi, but for the millions of people around the world who are counting on us. Read more on our Q3 results here: https://lnkd.in/ejgVYWYN #SanofiResults #Science #Innovation
